Jubilant Life Sciences is currently trading at Rs. 897.00, up by 34.70 points or 4.02% from its previous closing of Rs. 862.30 on the BSE.
The scrip opened at Rs. 886.00 and has touched a high and low of Rs. 909.75 and Rs. 881.00 respectively.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 909.75 on 04-Aug-2020 and a 52 week low of Rs. 230.00 on 25-Mar-2020.
Last one week high and low of the scrip stood at Rs. 909.75 and Rs. 731.00 respectively. The current market cap of the company is Rs. 13734.81 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 28.53% and 20.79% respectively.
Jubilant Life Sciences’ subsidiary — Jubilant Generics has launched remdesivir for injection under the brand name ‘JUBIR’ in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection). The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. The company’s 24 hour help line will enhance access to ‘JUBIR’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.
In order to increase accessibility of ‘JUBIR’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
